Dr. Jonathan Thompson

Doctor Overview

Dr. Jonathan Thompson is a doctor of medical oncology and hematology. He practices at the Clinical Cancer Center of Froedtert Hospital in Wisconsin. He is also an associate professor at the Medical College of Wisconsin (MCW). Dr. Thompson specializes in mesothelioma, among other cancers.

Dr. Thompson treats mesothelioma as part of Froedtert’s Thoracic Cancer Program. He strives to provide compassionate care to every patient and works closely with their loved ones. This includes offering virtual visits when possible. He develops custom mesothelioma care plans with up-to-date methods tailored to each case. For some patients, he may recommend clinical trials for emerging treatments.

Dr. Thompson is heavily involved in clinical research and trials. He leads the Immunotherapy Toxicity Team and is vice chair of MCW’s Solid-Tumor Early Phase Disease-Oriented Team. His publications include work on immunotherapy and biomarkers.

Dr. Thompson studies immunotherapy — a promising treatment for cancers like mesothelioma. For many mesothelioma patients, these types of trials have helped improve survival, quality of life and more. He can talk to patients about accessing approved immunotherapies or newer ones available through mesothelioma clinical trials.

Doctor Fast Facts

Main Specialty: Medical Oncology/Hematology

Other Interests & Specialties: Cellular therapy, chemotherapy, clinical trials, immunotherapy, lung cancer, mesothelioma, targeted therapy, thymoma and thymic tumors and Tumor Treating Fields.

Certifications, Awards & Accolades: Certified in Internal Medicine, Hematology and Medical Oncology through the American Board of Internal Medicine

Education & Experience:

• Medical Degree from the Medical College of Wisconsin
• Residency in Internal Medicine at Medical College of Wisconsin Affiliated Hospitals
• Fellowship in Hematology and Oncology at Medical College of Wisconsin Affiliated Hospitals

Publications

High-grade pneumonitis events in patients with unresectable, locally advanced nsclc treated with definitive chemoradiation followed by adjuvant durvalumab. JTO Clin Res Rep. 2024 Dec;5(12):100537.

Prolonged cancer control with adagrasib in patients with metastatic, krasg12c-mutated nsclc after sotorasib-induced hepatotoxicity: a case report. JTO Clin Res Rep. 2024 Apr;5(4):100661.